INT240689

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.15
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 5
Disease Relevance 1.31
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
arm 1
FCMTE1 (Homo sapiens)
Pain Link Frequency Relevance Heat
withdrawal 6 5.00 Very Low Very Low Very Low
addiction 3 5.00 Very Low Very Low Very Low
rheumatoid arthritis 3 5.00 Very Low Very Low Very Low
Angina 3 5.00 Very Low Very Low Very Low
Pain 3 5.00 Very Low Very Low Very Low
anesthesia 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Injury 23 97.20 Very High Very High Very High
Death 15 97.16 Very High Very High Very High
Disease 13 91.84 High High
Congenital Anomalies 3 91.12 High High
Scrapie 56 89.48 High High
Creutzfeldt Jakob Disease 24 78.92 Quite High
Syndrome 3 76.20 Quite High
Attention Deficit Hyperactivity Disorder 3 73.00 Quite High
Prion Diseases 18 49.88 Quite Low
Cardiovascular Disease 6 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Good compliance was demonstrated with the FaME programme and nearly two thirds of people participating in FaME continued in group exercise programmes for over a year after trial completion.
Gene_expression (programme) of FaME
1) Confidence 0.15 Published 2010 Journal Trials Section Body Doc Link PMC2821309 Disease Relevance 0.17 Pain Relevance 0
A Serious Adverse Event (SAE) is any adverse event occurring following study mandated procedures, having received the OEP or FaME programmes or usual treatment that results in any of the following outcomes:

(1) Death (2) A life-threatening adverse event (3) Inpatient hospitalisation or prolongation of existing hospitalisation (4) A disability/incapacity (5) A congenital anomaly in the offspring of a participant

Gene_expression (programmes) of FaME associated with congenital anomalies and death
2) Confidence 0.13 Published 2010 Journal Trials Section Body Doc Link PMC2821309 Disease Relevance 0.61 Pain Relevance 0
Participants in the usual care arm will not be offered either the OEP or FAME programmes.
Gene_expression (programmes) of FAME in arm
3) Confidence 0.13 Published 2010 Journal Trials Section Body Doc Link PMC2821309 Disease Relevance 0 Pain Relevance 0
The production and use of fatty acid methyl esters (FAME) as a fuel for diesel engines is a rapidly growing technology that has penetrated the transportation fuels sector in Europe and is in the process of doing so in the U.S. and other countries.
Gene_expression (production) of FAME
4) Confidence 0.06 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2493038 Disease Relevance 0.33 Pain Relevance 0
In situ transesterification has been described previously to be generally applicable for FAME synthesis from lipid-bearing materials such as MBM [17].
Gene_expression (synthesis) of FAME
5) Confidence 0.06 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2493038 Disease Relevance 0.20 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox